Biomolecular targets for platinum antitumor drugs

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Cis-diamminedichloroplatinum(II) (cisplatin) is a cornerstone chemotherapy agent for various cancers.
• Second-generation platinum-based drugs are in clinical use or trials, expanding treatment options.
• The established mechanism involves cell cycle arrest at G2 and apoptosis, primarily linked to DNA binding.

Purpose of the Study:

• To review the established DNA binding mechanism of platinum-based drugs.
• To discuss the role of protein and enzyme interactions in platinum drug efficacy and toxicity.
• To encourage research into the broader metallobiochemistry of platinum drugs beyond DNA interactions.

Main Methods:

• Literature review and synthesis of existing research on platinum-based anticancer drugs.
• Analysis of studies focusing on DNA, protein, and enzyme interactions.
• Discussion of apoptosis pathways influenced by platinum compounds.

Main Results:

• While DNA binding is a key anticancer mechanism, platinum drugs also interact with proteins and enzymes.
• These interactions with proteins and enzymes contribute to both therapeutic effects and toxic side effects.
• The precise mechanisms involving protein and enzyme interactions are complex and multifaceted.

Conclusions:

• Understanding platinum drug mechanisms requires considering interactions beyond DNA.
• Further research into metallobiochemistry is crucial for developing more effective and less toxic platinum-based therapies.
• Exploring cellular and molecular events beyond DNA binding will enhance our comprehension of apoptosis and drug action.